Annexon's ARCHER data will pick who enrolls in pivotal ARCHER II readout
A Phase 2 baseline-characteristics analysis of vonaprument in geographic atrophy sets up the enrollment logic behind Annexon's 659-patient Phase 3 trial, due to read out in the fourth quarter of 2026.
Executive Summary
- Annexon is presenting a sub-analysis of its completed Phase 2 trial that identifies which baseline patient characteristics were tied to vision loss, work the company says shaped who was enrolled in its ongoing pivotal trial.
- The link matters because the pivotal trial's outcome, expected before year-end, is what determines whether the earlier positive signal in geographic atrophy translates into a registrational result.
- No other clinical-stage program targets this same mechanism in this disease, so the readthrough from this analysis stays inside Annexon's own pipeline rather than reshaping a broader competitive field.
- The completed Phase 2 trial already reported a statistically significant, dose-dependent effect on a prespecified functional vision endpoint, along with structural retinal protection and a favorable safety readout through twelve months.
The presentation
Annexon, Inc. (Nasdaq: ANNX) will give an oral presentation titled "Baseline Characteristics Associated with Loss of BCVA ≥15 ETDRS Letters in Participants with Geographic Atrophy in the Phase 2 ARCHER Study" at the ASRS 44th Annual Scientific Meeting in Montreal on July 18, 2026. The presenter, Margaret Chang, M.D., of Retinal Consultants Medical Group, will detail which baseline factors predicted a loss of best corrected visual acuity (BCVA) of 15 or more letters, the trial's key functional threshold. Annexon says the analysis informed patient population selection for the ongoing Phase 3 ARCHER II trial. AnnexonAnnexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best ...Jul 14, 2026
The trial behind it
ARCHER (NCT04656561) is a completed, randomized, multi-center, double-masked, sham-controlled Phase 2 trial that enrolled 270 patients with geographic atrophy secondary to dry age-related macular degeneration. The trial's registered primary outcome measure was GA lesion growth rate, an anatomic endpoint. Annexon's own disclosure reports that vonaprument (formerly ANX007) produced statistically significant, time- and dose-dependent protection from confirmed BCVA loss of 15 or more letters, along with improvements on low luminance visual acuity and low luminance visual deficit, and photoreceptor protection measured by optical coherence tomography. The company also reported the drug was generally well tolerated through month 12, with no increase in choroidal neovascularization between treated and sham arms and no retinal vasculitis events. NCT04656561+1A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic AtrophyNCT04656561Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best ...Jul 14, 2026
What comes next
The Phase 3 ARCHER II trial is an ongoing, global, pivotal, sham-controlled, double-masked study enrolling 659 patients with geographic atrophy, with enrollment completed in July 2025. Annexon expects topline pivotal data from ARCHER II in the fourth quarter of 2026. Vonaprument carries FDA Fast Track designation and European Medicines Agency PRIME designation, the first such PRIME grant for a geographic atrophy candidate. AnnexonAnnexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best ...Jul 14, 2026
The competitive frame
No other industry-sponsored trial pairs the C1q target with geographic atrophy; Annexon's own program is the only Phase 2 or later asset in this specific target-indication combination. The broader geographic atrophy field includes mechanistically distinct programs such as Regeneron's cemdisiran, a C5-targeting RNA therapy in Phase 3, and Belite Bio's tinlarebant, a small-molecule RBP4 modulator also in Phase 3, neither of which shares vonaprument's complement C1q mechanism. That mechanistic isolation means the ARCHER II readout will test the C1q-blocking hypothesis largely on its own, without a same-target precedent to benchmark against.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.